Dengue Seroprevalence Study in Blood Donors in the French West Indies (DengSeroprevAn)

August 16, 2021 updated by: RICHARD, Etablissement Français du Sang, Martinique
Dengue is an infectious disease most prevalent in the world. This disease is endemic in the Caribbean, with an increase in seasonal rains. Several outbreaks have been observed in recent years, in 2001, 2005 and 2007, during which further particularly virulent serotypes have emerged. The clinical expression of dengue fever is variable, ranging from no symptoms to a classical form with fever, and even of severe or lethal bleeding. With the possible existence of silent forms of the disease, there are no data identifying the current level of protection of the population in Martinique / Guadeloupe.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

  1. Principal objective:

    To estimate the prevalence of the specific antibodies of the dengue (IgG) in blood donors in the French West Indies.

  2. Secondary objective:

To specify the serotypic specificity of the anti-dengue antibodies detected during the study.

Study Type

Observational

Enrollment (Actual)

817

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Guadeloupe
      • Pointe-à-Pitre, Guadeloupe, 97171
        • French Blood Establishment of Guadeloupe
  • Martinique
      • Fort-de-France, Martinique, 97264
        • French Blood Establishment of Martinique

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult, résidents in Martinique/ Guadeloupe (french west indies), aged 18 to 65 years coming to give their blood in one of the building or mobile collection facilities of the French Blood Establishment in French West Indies.

Description

Inclusion Criteria:

  • Eligible for blood donation following the French legislation,
  • Resident in Martinique /Guadeloupe for at least one year
  • Consent signed

Exclusion Criteria:

  • Not Eligible for blood donation following the French legislation,
  • Not Resident in Martinique / Guadeloupe for at least one year
  • Consent not signed

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Presence or not of dengue virus-specific immunoglobulin G antibodies
Time Frame: 1 day
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Characterization of dengue virus serotype-specific IgG
Time Frame: 1 day
Characterization of dengue virus serotype-psecific IgG whendengue virus serotype-specific immunoglobulin G antibodies Test is positive
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Etablissement Français du Sang, Martinique

Collaborators

Institut National de la Santé Et de la Recherche Médicale, France
Sanofi Pasteur, a Sanofi Company
Clinique Antilles-Guyane

Investigators

  • Principal Investigator: Pascale RICHARD, MD, French Blood Establishment of Martinique

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2011

Primary Completion (Actual)

May 1, 2011

Study Completion (Actual)

May 1, 2012

Study Registration Dates

First Submitted

April 14, 2010

First Submitted That Met QC Criteria

April 14, 2010

First Posted (Estimate)

April 15, 2010

Study Record Updates

Last Update Posted (Actual)

August 20, 2021

Last Update Submitted That Met QC Criteria

August 16, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 10/B/01
  • 2010-A00385-34 (Other Identifier: AFSSAPS (ANSM))

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dengue

Clinical Trials on Biological sample collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe